Official Title: “A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of MK0736 and MK0916 in Hypertensive Patients”

The objective of this study is to evaluate the safety and efficacy of two investigational drugs in lowering blood pressure and body weight in patients with hypertension (high blood pressure).

This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants).

Study Type: Interventional

Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Study Primary Completion Date: January 2007

Intervention(s) in this Clinical Trial

• Drug: MK0736
• Drug: MK0916

Primary Measures

• Reduction in blood pressure, safety and tolerability

Secondary Measures

• Waist circumference, dose comparison

Inclusion Criteria:

• Hypertension SBP </= 160mm Hg and DBP: 90-105mm Hg

Exclusion Criteria:

• Pre-menopausal women
• patients currently taking more than two (2) blood pressure lowering medications
• Body Mas Index (BMI)>40 kg/m2 (morbidly obese patients)
• History of Alcohol abuse (<3 Years)
• History of diabetes,chronic kidney disease, Active liver disease, recent heart attack or stroke

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: 65 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: Merck

Overall Clinical Trial Officials and Contacts

Medical Monitor Study Director Merck  

Information obtained from ClinicalTrials.gov on February 04, 2010

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00274716

Study ID Number: 2006_004

ClinicalTrials.gov Identifier: NCT00274716

Health Authority: United States: Food and Drug Administration